MGX METAGENOMI THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, METAGENOMI THERAPEUTICS INC reported revenue of n/a, net income of −$27.5M and diluted EPS of −$0.73; for the fiscal year ended December 2025 revenue was $25.2M, down 51.8% on the year before.
MGX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $25.2M, gross profit n/a, operating income −$96.0M, net income −$87.9M (margin -348.5%), EPS −$2.36
- Fiscal year ended Dec 2024: revenue $52.3M, gross profit n/a, operating income −$88.9M, net income −$78.1M (margin -149.3%), EPS −$2.36
- Fiscal year ended Dec 2023: revenue $44.8M, gross profit n/a, operating income −$78.5M, net income −$68.3M (margin -152.5%), EPS −$20.05
MGX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$27.5M, EPS −$0.73
- Quarter ended Mar 31, 2026: revenue $1.25M (down 69.8% year over year), net income −$23.1M, EPS −$0.61
- Quarter ended Dec 31, 2025 (from the annual report): revenue $3.91M (down 59.3% year over year), net income −$22.5M, EPS −$0.59
- Quarter ended Sep 30, 2025: revenue $8.66M (down 24.8% year over year), net income −$20.4M, EPS −$0.55
- Quarter ended Jun 30, 2025: revenue $8.51M (down 57.5% year over year), net income −$19.9M, EPS −$0.54
- Quarter ended Mar 31, 2025: revenue $4.13M (down 63.0% year over year), net income −$25.0M, EPS −$0.68
- Quarter ended Dec 31, 2024 (from the annual report): revenue $9.61M (down 22.5% year over year), net income −$23.4M, EPS −$0.37
- Quarter ended Sep 30, 2024: revenue $11.5M (down 6.9% year over year), net income −$18.8M, EPS −$0.51
- Quarter ended Jun 30, 2024: revenue $20.0M (up 76.5% year over year), net income −$10.7M, EPS −$0.29
- Quarter ended Mar 31, 2024: revenue $11.2M (up 28.9% year over year), net income −$25.1M, EPS −$1.19
- Quarter ended Dec 31, 2023 (from the annual report): revenue $12.4M, net income −$19.3M, EPS −$5.67
- Quarter ended Sep 30, 2023: revenue $12.4M, net income −$19.8M, EPS −$5.82
- Quarter ended Jun 30, 2023: revenue $11.3M, net income −$13.0M, EPS −$3.82
- Quarter ended Mar 31, 2023: revenue $8.66M, net income −$16.1M, EPS −$4.74
MGX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$88.9M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$109M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$91.4M, share buybacks n/a
MGX balance sheet
- Jun 30, 2026: cash $39.0M, total assets $174M, total liabilities $61.1M, shareholders' equity $113M
- Mar 31, 2026: cash $25.3M, total assets $197M, total liabilities $59.2M, shareholders' equity $138M
- Dec 31, 2025: cash $41.7M, total assets $221M, total liabilities $62.5M, shareholders' equity $159M
- Sep 30, 2025: cash $32.8M, total assets $248M, total liabilities $69.5M, shareholders' equity $178M
- Jun 30, 2025: cash $26.9M, total assets $272M, total liabilities $76.5M, shareholders' equity $196M
- Mar 31, 2025: cash $29.2M, total assets $298M, total liabilities $85.2M, shareholders' equity $213M
- Dec 31, 2024: cash $27.4M, total assets $325M, total liabilities $89.7M, shareholders' equity $235M
- Sep 30, 2024: cash $25.1M, total assets $358M, total liabilities $103M, shareholders' equity $256M
What is MGX's revenue?
METAGENOMI THERAPEUTICS INC reported $25.2M of revenue for the fiscal year ended December 2025.
Is MGX profitable?
No. METAGENOMI THERAPEUTICS INC lost $93.5M over the last four quarters.
What is MGX's EPS?
Diluted earnings per share over the last four quarters were −$2.48; −$0.73 in the latest quarter.